Clinically relevant CTD assays, made with the quality you expect.
Make a difference aiding in the diagnosis of connective tissue disease and order EliATM CTD assays for laboratory testing today.
Fully automated solid-phase fluorescence enzyme immunoassays (FEIA)
EliA SymphonyS [defined ANA screen]
Contains testing for: U1-RNP (A, C, 70 kDa), SS-A/Ro (52 kDa, 60 kDa), SS-B/La, Topoisomerase I/Scl-70, Histidyl-tRNA-synthetase/Jo-1, Centromere, and SmD3)
EliA U1RNP [U1-RNP (A, C, 70 kDa)]
EliA SmDP-S [SmD3]
EliA Ro [SS-A/Ro (52 kDa, 60 kDa)]
EliA La [SS-B/La]
EliA CENP [Centromere]
EliA Scl-70S [Topoisomerase I/Scl-70]
EliA Jo-1 [Histidyl-tRNA-synthetase/Jo-1]
EliA dsDNA [dsDNA]
EliA RNA Pol III [RNA Polymerase III]
EliA Rib-P [Ribosomal P-protein/Rib-P]
EliA RNP70 [RNP70]
EliA Ro52 [SS-A/Ro (52 kDa)]
EliA Ro60 [SS-A/Ro (60 kDa)]
Become a trusted source for CTD diagnostics today.
Arm your lab with a menu of clinically relevant CTD markers:
EliA™ Autoimmunity portfolio features assays that aid in the diagnosis of a variety of different connective tissue diseases, helping your lab support accurate diagnoses.
Table citations1-11
Become the pinnacle of diagnostic credibility.
EliA™ CTD testing offers assays backed by clinical research.
“…the EliA™ Symphony demonstrated excellent sensitivity for anti-ENA reactivities in SLE and SSc patients.”
- Journal of Clinical and Experimental Rheumatology12
“…the association of the CTD screen test to the ANA-IIF… increases the diagnostic sensitivity from 89% to 97% and the diagnostic specificity from 65% to 98%...”
- Autoimmunity Reviews13
“In our opinion, EliA™ dsDNA has the best combination of sensitivity and specificity which makes it very adequate for diagnosis and follow-up.”
- Journal of Clinical Chemistry and Laboratory Medicine14
EliA SymphonyS
A defined ANA screen, making it easier for your providers to order what they need.
Increase your lab’s test volume by making CTD test ordering simpler and more concise.
How can EliA CTD portfolio elevate ANA testing?
Combining the power of Helios® Automated IFA Systems and CTD portfolio
Thermo Fisher Scientific is the official US distributor of Helios systems and AESKUSLIDES®
Let the Phadia 250 system be the backbone in maximizing your lab’s workflow.
Exceptional balance of specificity and sensitivity
Antigens used in EliA CTD assays are manufactured using innovative human recombinant protein technology, which optimizes accessibility and purity, aiding clinicians in making impactful and appropriate decisions.15-17
High quality assays, aiding in antibody identification15-17
Even for difficult-to-detect antibodies, such as anti-SS-A/Ro or anti-Jo-1, high quality EliA antigens can help identify important antibodies associated with CTD.18-19
Less false positives
High specificity due to the selection and use of recombinant antigens in this portfolio means laboratories can help reduce the number of false positives, aiding clinicians in prescribing appropriate therapies.15
Quality. Accuracy. Clinically relevant.
Our autoimmunity and laboratory experts are here to help you elevate your lab.
Gain the benefits of Phadia Laboratory Systems by adopting EliA CTD assays20-22
More time testing
Less upkeep
28-day master calibration curves stored for every isotype (IgG, IgA, IgM)
Increased walkaway time
Reduced labor costs
Low hands-on time during start up and automatic shutdown and rinse capabilities
More lab space
Less waste
Ability to run ImmunoCAP™ Allergy solutions and EliA Autoimmunity solutions on the same instrument
Clinicians trust you. Patients depend on you.
Let us help support you.
Your partner in autoimmunity diagnostics
Unlock your lab’s potential with Phadia Instruments today.
- Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012;2012:606195. doi: 10.1155/2012/606195. Epub 2012 Dec 6. PMID: 23304190; PMCID: PMC3523155.
- Conti F, Ceccarelli F, Perricone C, et al. Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort. Mediators Inflamm. 2015;2015:328078. doi:10.1155/2015/328078
- Peng SL and Craft JE. Autoantibodies 1996, pp 774-782.
- Gerli L and Caponi L. Autoimmunity 2005
- Rao L, Liu G, Li C, et al. Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus. Exp Ther Med. 2013;5(6):1710‚Äê1714. doi:10.3892/etm.2013.1051
- Tan EM. Immunologist 1999
- Nikpour M, et al. Arthritis Research & Therapy 2011
- Martins Rocha T, Fonseca R, et al AB0645 Anti-Ssa/ro Antibodies in A Cohort of Systemic Sclerosis Patients: The Association with Interstitial Lung Disease Annals of the Rheumatic Diseases 2016;75:1125
- Ihn H, et al. Clin Exp Immunol.1996
- Cruellas MG, Viana Vdos S, Levy-Neto M, Souza FH, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo). 2013;68(7):909-914. doi:10.6061/clinics/2013(07)04
- Robbins, Ailsa et al. "Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases." Frontiers in immunology vol. 10 444. 12 Mar. 2019, doi:10.3389/fimmu.2019.00444
- Van Praet JT, Vander Cruyssen B, Bonroy C, Smith V, Delanghe J, De Keyser F. Validation of a new screening strategy for anti-extractable nuclear antigen antibodies. Clin Exp Rheumatol. 2009 Nov-Dec;27(6):971-6. PMID: 20149314.
- Bizzaro N, et al. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. Autoimmun Rev. 2018 Jun;17(6):541-547. doi: 10.1016/j.autrev.2017.12.007. Epub 2018 Apr 7. PMID: 29631063.
- Hernando M, González C, Sánchez A, Guevara P, Navajo JA, Papisch W, González-Buitrago JM. Clinical evaluation of a new automated anti-dsDNA fluorescent immunoassay. Clin Chem Lab Med. 2002 Oct;40(10):1056-60. doi: 10.1515/CCLM.2002.185. PMID: 12476949.
- Orme ME, Andalucia C, Sjolander S, Bossuyt X. A comparison of a fluorescence enzyme immunoassay versus indirect immunofluorescence for initial screening of connective tissue diseases: Systematic literature review and meta-analysis of diagnostic test accuracy studies. Best Pract Res Clin Rheumatol. 2018;32(4):521-34.
- van der Pol P, Bakker-Jonges LE, Kuijpers J, Schreurs MWJ. Analytical and clinical comparison of two fully automated immunoassay systems for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta. 2018;476:154-9.
- Alsaed OS, Alamlih LI, Al-Radideh O, Chandra P, Alemadi S, Al-Allaf AW. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases. Sci Rep. 2021;11(1):8229.
- Bossuyt, Xavier, and Ariane Luyckx. “Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples.” Clinical chemistry vol. 51,12 (2005): 2426-7. doi:10.1373/clinchem.2005.058552
- Agmon-Levin, Nancy et al. “International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.” Annals of the rheumatic diseases vol. 73,1 (2014): 17-23. doi:10.1136/annrheumdis-2013-203863
- Phadia® 250 User Manual 12-3904-01/EN Edition 2.2. published 2017 Sep.
- Phadia® 2500 and Phadia 5000® User Manual EN Edition 1.1. published 2012 March
- Phadia® 1000 User Manual 12-3803-01/EN Edition 2.6. published 2020 July
